Data-driven tool predicts high-risk periods for metastatic breast cancer patients

Oncologists have long recognized that aggressive chemotherapy offers little benefit to patients who are in the terminal phase of metastatic breast cancer, yet pinpointing the moment when a disease has entered that stage remains a clinical challenge. Advances in targeted therapies and immunotherapies have extended survival for many patients, expanding the array of treatment options and complicating the assessment of when curative intent should give way to palliative focus. As a result, physicians frequently overestimate life expectancy, a discrepancy that can postpone essential end‑of‑life discussions and delay the introduction of supportive‑care services.

The uncertainty surrounding prognosis contributes to delayed conversations about goals of care, advance directives, and symptom management, leaving patients and families without timely guidance. Experts emphasize that more accurate survival predictions and earlier integration of hospice and palliative resources are needed to align treatment plans with patients’ preferences and improve quality of life during the final months of illness.